KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
25 hedge funds and large institutions have $61.6M invested in KalVista Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 24 → 25 (+1)
0.11% more ownership
Funds ownership: 60.09% → 60.21% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $63.2M → $61.6M (-$1.62M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2M |
| 2 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$473K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$429K |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$425K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$31.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$1.76M |
| 2 |
Renaissance Technologies
New York
|
-$474K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$427K |
| 4 |
Goldman Sachs
New York
|
-$151K |
| 5 |
JP Morgan Chase
New York
|
-$85.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Goldman Sachs
New York
| – | -$151K | -15,528 | Closed |
|
27
Barclays
London,
United Kingdom
| – | -$13K | -1,349 | Closed |
|
|
CHP
28
Cable Hill Partners
Portland,
Oregon
| – | -$11K | -1,000 | Closed |
|
KALV Hedge Fund Activity: Q1 2018 in Review
25 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2018, worth a combined $61.6M — down 2.6% from $63.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new KALV positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $2M. The largest seller was Nexthera Capital, exiting entirely with an estimated $1.76M sold.
- 25 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2018, up from 24 in Q4 2017.
- Funds reported $61.6M of KalVista Pharmaceuticals stock for Q1 2018, down 2.6% quarter-over-quarter.
- 5 funds opened new KalVista Pharmaceuticals positions in Q1 2018 and 4 closed out, a net change of +1 holder.
- The largest KalVista Pharmaceuticals buyer in Q1 2018 was Eventide Asset Management, an estimated $2M added.
- The largest KalVista Pharmaceuticals seller in Q1 2018 was Nexthera Capital, an estimated $1.76M sold.
Based on aggregated 13F filings for Q1 2018.